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Abstract
Purpose of Review Amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD) spectrum disorder is a rare fatal
disease with strong genetic influences. The implementation of short-read sequencing methodologies in increasingly large patient
cohorts has rapidly expanded our knowledge of the complex genetic architecture of the disease. We aim to convey the broad
history of ALS gene discovery as context for a focused review of 11ALS gene associations reported over the last 5 years.We also
summarize the current level of genetic evidence for all previously reported genes.
Recent Findings The history of ALS gene discovery has occurred in at least four identifiable phases, each powered by different
technologies and scale of investigation. The most recent epoch, benefitting from population-scale genome data, large interna-
tional consortia, and low-cost sequencing, has yielded 11 new gene associations. We summarize the current level of genetic
evidence supporting these ALS genes, highlighting any genotype-phenotype or genotype-pathology correlations, and discussing
preliminary understanding of molecular pathogenesis. This era has also raised uncertainty around prior ALS-associated genes
and clarified the role of others.
Summary Our understanding of the genetic underpinning of ALS has expanded rapidly over the last 25 years and has led directly
to the clinical application of molecularly driven therapies. Ongoing sequencing efforts in ALS will identify new causative and
risk factor genes while clarifying the status of genes reported in prior eras of research.
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ALS genetics
The ALS-FTD Spectrum of Disease Has
Complex Genetic Architecture
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease clinically recognized for progressive paralysis due to
the degeneration of spinal cord and cortical motor neurons [1].
Even with improvements in the multi-disciplinary care of pa-
tients and two medications approved by the FDA, ALS is
invariably fatal due to respiratory failure, with patients surviv-
ing a median of 3 years after symptom onset. The clinical
picture of a typical ALS patient is so dominated by mounting
motor disability that ALS historically been considered a “mo-
tor neuron disease.” This nomenclature likely delayed recog-
nition that ALS is a multisystem disease in which a range of
non-motor neuronal populations can also be affected [2, 3].
The most commonly involved non-motor neurons are those
regulating fronto-executive cognitive function; more than half
of ALS patients develop fronto-executive dysfunction during
the course of the disease with 5–10% meeting criteria for
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fronto-temporal dementia (FTD) [4–7]. In addition to frequent
clinical co-occurrence, the ALS-FTD spectrum shares an in-
creasing number of genetic causes and underlying neuropa-
thology (mislocalized and aggregated TDP-43 protein) [8, 9].
This pathological hallmark makes the ALS-FTD spectrum of
disease one among many neurodegenerative diseases that are
characterized by pathological protein aggregates, the so-called
proteinopathies.
Knowledge of key biological pathways important to ALS-
FTD pathogenesis has been greatly advanced by progress in
uncovering causative genes and genetic risk factors for the
disease. From the very first published case series, familial
ALS (fALS) has been recognized, with 7–10% of individuals
having a family history of either ALS or FTD [10]. It is within
these families that the bulk of monogenic causes have been
found. However, 85–90% of ALS patients, so-called sporadic
ALS (sALS), have no known family history and typically do
not carry rare and high penetrant mutations in known genes.
Genetic factors influence disease propensity in this group as
well, with studies showing polygenic risk frommany common
variants [11, 12] or, as suggested by preliminary data, for
smaller numbers of larger effect variants (so-called
oligogenic inheritance) [13, 14]. Thus, the genetic structure
of ALS is proving to be complex, with a broad range of allele
frequencies and effect sizes (reviewed in [15]).
Timeline of Gene Discovery in ALS
Since Charcot described motor neuron disease in the late
1800s, over 40 ALS genes have now been associated with
ALS, explaining 25–35% of FALS and 5–10% of apparent
SALS. Genetic discoveries in ALS have occurred in four dis-
tinguishable epochs, each leveraging important methodologi-
cal advances (Fig. 1).
In the first era (c.1990–1999), gene discovery required
large ALS families powered for high-resolution linkage anal-
ysis followed by the arduous task of positional cloning and
sequencing. Accordingly, discoveries came slowly in this era
for all human diseases and yielded only a single gene for
typical ALS, SOD1 [16].
Publication of the human genome inaugurated the second era
(c.2000–2008). As an exhaustive compendiumof genes and their
genomic location, the draft genome allowed a simple database
query to replace time-consuming positional cloning (ALS2, [17]).
Genes within a linkage peak could be quickly prioritized for
sequencing based on predicted biological roles. Large families
were still required to identify ALS-associated loci but
hypothesis-driven candidate gene sequencing could now be pur-
sued. Candidate genes could be those causing other human dis-
eases with phenotypic overlap (DCTN1, GRN, CHMP2B, FIG
4), implicated by neuropathological analysis of human tissues
(TARDBP, PRPH), biomarker investigations (ANG), or insights
from mouse models of ALS. During this era, the availability of
increasingly cheap genome-wide genotyping of common vari-
ants made unbiased genome-wide association studies (GWAS)
possible [18]. Instead of depending on large families, the success
of candidate gene and GWAS methods hinge on large numbers
of DNA samples and replication in additional cohorts. This fact
prompted organized efforts to collect and bank samples from
patients, family members, and controls (predominantly of
European ancestry). Some of these efforts (e.g., the NINDS
MND collection housed at Coriell) recognized the importance
of consenting participants for broad sample and data sharing,
Fig. 1 Strategies for the
identification of ALS genes.
Strategies have evolved from
individual gene mapping to
increasingly powered
technological and statistical
methodologies. Since the
implication of SOD1, 42
additional genes have been
implicated in ALS to date with
variable genetic support in
replication and functional studies.
GWAS, genome-wide association
studies; WES, whole-exome
sequencing; WGS, whole-
genome sequencing
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ensuring some cohorts would follow an open-access model rath-
er than remaining in the hands of single institutions or consortia.
During this era, nearly a dozen geneswere reported to causeALS
and common variations at a dozen loci were implicated by
GWAS. Only two of these associations have been repeatedly
replicated (the region around C9ORF72 and at UNC13A, with
OR~ 1.2 each [12, 19••]), but the evidence for others has either
rejected an association or been inconclusive.
The explosion in sequencing speed and reduction in costs
brought by “next-generation” short-read sequencing methods
ushered in the third era (c.2009–2014) by permitting the rapid
and simultaneous sequencing of larger numbers of genes
(targeted panels and whole exomes) in increasing numbers
of ALS patients. Studies could rapidly identify mutated genes
within a locus implicated by linkage in larger ALS families, if
they could be found—families with DNA from multiple af-
fected individuals were increasingly scarce [20].
Alternatively, families too small for linkage could be analyzed
for recurrently mutated genes. Because whole-exome se-
quencing returned genome-wide mutational data, it was
learned that several other known non-ALS disease genes had
ALS presentations within their phenotypic spectrum (VCP,
MATR3). These methods also showed that portions of the
ALS population carried potentially pathogenic variants in
more than one ALS gene and possibly represented oligogenic
inheritance [14, 21]. This era also saw the first use of whole-
genome sequencing (WGS) and repeat-primed PCR to discov-
er the most common cause of ALS to date, expansions of a
GGGGCC hexanucleotide repeat in the C9orf72 gene [22,
23], and even larger-scale and increasingly prospective DNA
sample collections (e.g., Project MinE), including in non-
European populations. More than 15 genes and additional
GWAS loci were reported in this 5-year period, but approxi-
mately one-third of these associations remain uncertain pend-
ing additional replication and/or functional studies.
As panels of known ALS genes became inexpensive and
diverse geoancestry cohorts assembled, a fuller characterization
of gene mutation frequencies in both familial and “sporadic”
patients have revealed important differences between ancestries
[24]. For example, ~ 60% of European families are explained by
known genes (C9ORF72>>SOD1>>TARDBP>FUS), while in
Asia, the 40% of families that are currently explained have a
different causative gene distribution (SOD1>>>FUS>
TARDBP>C9ORF72). Mutations in these same genes can be
found in ~ 8% of “sporadic” European pat ients
(C9ORF72>>>>SOD1>>TARDBP>FUS) and ~ 3% in Asian
populations (SOD1>>FUS>TARDBP=C9ORF72) [25].
The fourth and current era (c.2015 onward) has been en-
abled by the large and well-annotated sample repositories fo-
cused on simplex/sporadic cases, broader data sharing/
consortia efforts, and the falling costs of whole-genome se-
quencing. Ever larger GWA studies have validated known
loci and provided strong evidence for new regions [12,
19••], while comprehensive ALS gene ascertainment has con-
tinued uncovering individuals with possible oligogenic ALS
[21, 26]. By far the biggest advance in ALS gene discovery
has been the application of improved statistical frameworks
for genome-wide rare variant case-control studies (e.g., col-
lapsing analysis, rare-variant burden testing [27, 28, 29••].
The ability to identify genes or other genomic regions
enriched for mutations in ALS has played a role in implicating
at least 11 new ALS-associated genes including TBK1,
TUBA4A, KIF5A, ANXA11, TIA1, CCNF, DNAJC7, NEK1,
C21orf2, LGALSL, and GLT8D1. These genes are summa-
rized below, focusing on the strength of genetic and functional
evidence, genotype-phenotype correlations, proposed mecha-
nisms by which these genes could lead to neurodegeneration,
and gaps in our understanding that need filling by future
investigation.
Many ALS Genes Highlighting Key Shared
Pathways
By overlapping the known functions of causative ALS genes,
the field has gained valuable insight into key cellular path-
ways underlying the pathogenesis of the disease. Although
many pathways are highlighted by the genetics of ALS, sev-
eral are overwhelmingly implicated by the convergence of
multiple genes. These include RNA processing, proteostasis,
neuroinflammation, vesicle trafficking, and axonal transport.
RNA Processing and Metabolism
TARDBP (Tar DNA binding protein 43 kDa; encoding TDP-
43 protein) and FUS encode “prion-like domain” (PLD)–con-
taining proteins with increased aggregation propensity that
carry key functions in RNA processing. Predominantly local-
ized to the nucleus, their ability to shuttle between the nucleus
and cytosol is compromised in ALS, resulting in pathological
TDP-43 and FUS inclusions in the cytosol (reviewed in [30]).
Mutations in the genes themselves (TDP-43 C-terminal do-
main) remain rare [31], yet TDP-43 protein deposition within
insoluble cytoplasmic inclusions is seen in almost all SALS
cases, while a minority of FALS cases present instead FUS
and SOD1 deposition, with SOD1/FUS and TDP-43 deposi-
tion being mutually exclusive. TDP-43 aggregation and
pathomechanisms are therefore more widely applicable to
our understanding of the pathogenesis of ALS [32, 33].
Misfolding and accumulation into cytoplasmic non-
functional aggregates of RNA-binding proteins involved in
all steps of mRNA transcription, processing, storage, and deg-
radation have severe consequences in multiple cell types. The
loss of TDP-43 and FUS from the nucleus (“loss-of-func-
tion”), the formation of protein aggregates (“gain-of-func-
tion”), and a combination of both have been implicated in
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ALS. Loss-of-function mechanisms include dysregulation in
RNA metabolism, splicing, and mRNA transport (via
hnRNPs for TDP-43 and ELAV-4 for FUS) [34, 35].
Mutations in TARDBP can exhibit disease-causing effects in
a toxic gain-of-function manner too: misfolding and accumu-
lation of TDP-43 in the cytoplasm sequester mRNA transport
proteins and even directly sequester mRNAs into aggregates,
impeding efficient mRNA transport in the long processes of
astrocytes and neurons, thereby disrupting essential functions
away from the nucleus [36]. In addition to TDP-43 or FUS
ubiquitylation, aging, or cellular stress factors, genetic factors
related to cellular architecture have emerged as central under-
lying contributors to ALS pathology. A role for nuclear import
(Nup proteins) and dysfunction in stress granule (SG) dynam-
ics in seeding TDP-43 aggregation has crystallized recently
with mutations in TIA1 and CCNF [37], see below).
Tankyrase-1/2 inhibitor Veliparib was found to mitigate cyto-
plasmic accumulation of TDP-43 in SGs in mammalian sys-
tems, likely by inhibiting PARylation of SGs and allowing
TDP-43 to shuttle back to the nucleus offering a potential
therapeutic target [38]. The specificity of the mechanism of
action will be interesting to test as hnRNPA1, another RBP
and ALS gene, undergoes PARylation for nucleocytoplasmic
shuttling [39]. The interplay between TDP-43 aggregation,
SGs, and the nuclear membrane is not restricted to ALS and
develops as a common theme in neurodegeneration with sim-
ilar involvements of SGs and the nuclear pore in Tau and
TDP-43 pathology in Alzheimer disease [40, 41].
Proteostasis
Cellular stress and subsequent pathological protein misfolding
are a common pattern in all neurodegenerative diseases, in-
cluding ALS-FTD where aggregated TDP-43 and other
misfolded proteins are pathological hallmarks [33]. Many
established ALS genes play key roles in regulating autophagy
or the ubiquitin-mediated pathways for degrading misfolded
proteins. These includeOPTN, SQSTM1, UBQLN2, and VCP.
Several of the newly reported genes also act in these path-
ways. TBK1 is a clear regulator of autophagy and directly
interacts with OPTN [42]. DNAJC7 is a heat shock protein
whose mutations may disrupt its ability to act as an effective
intracellular chaperone, possibly resulting in increased burden
of protein misfolding in ALS-FTD [28]. TIA1 plays a key role
in the nucleation of stress granules [43], which are emerging
as a potential nidus for the aggregation of TDP-43 and other
ALS-related proteins FUS and hnRNPs [44–46]. CCNF en-
codes a protein called cyclin F, a binding partner of another
ALS-associated protein VCP. A recent study demonstrated
that, in cell culture, CCNF mutations may contribute to ALS
pathogenesis by increasing the ATPase activity of VCP in the
cytoplasm, which in turn increases TDP-43 aggregation [47].
Neuroinflammation
The role of microglia and other effector cells of the immune
system has been well recognized from human neuropatholog-
ical and animal modeling data. Perhaps the recent genetic
validation of its importance comes from the discovery of mu-
tations in TANK-binding Kinase (TBK1). A primary function
of TBK1 is to activate autophagy and inflammatory pathways
in response to pathogen exposure (mediated through activa-
tion of both NF-kB and interferon signaling). The complex
role of neuroinflammation in ALS is illustrated by mouse
studies of the interaction between TBK1 and SOD1: loss of
one copy of TBK1 precipitated earlier disease onset with im-
paired autophagy but counter-intuitively extended survival by
reducing inflammatory activation in later stages of disease
[48, 49]. These studies appear to provide evidence for the
deleterious effects of neuroinflammation in late disease,
highlighting the therapeutic potential of targeted anti-
inflammatory therapies as disease-modifying agents.
Impaired Axonal Transport
Maintaining adequate axonal transport is crucial in large cells
such asmotor neurons and is known to be dysregulated in ALS
[50]. Axonal transport requires the assembly and maintenance
of microtubule networks that act as transport highways, facil-
itating the anterograde and retrograde movement of cargo, in-
cluding mRNAs, organelles, proteins, and much more. NEK1,
through its interactions with FEZ1 and FEZ2, has been shown
to be involved in pathways crucial to the maintenance, growth,
and repair of these networks with mutations demonstrating
impaired microtubule stability [51]. Furthermore, mutations
in TUBA4A examined in cell culture demonstrated an impair-
ment in microtubule network assembly and reduction in mi-
crotubule stability [52]. Mutations inKIF5A are also thought to
result in impaired axonal transport as KIF5A is a kinesin, a
microtubule-associated motor protein, responsible for organ-
elle transport, including lysosomes [19••]. Cells also rely on
local translation of mRNAs to respond to local stimuli without
the need for global changes in the cellular environment [32].
Local translation of mRNAs is reliant on efficient mRNA
transport along axons. A recently identified ALS-associated
gene, ANXA11 [53], is responsible for tethering mRNAs as
part of an RNA granule complex to actively transported lyso-
somes, enabling them to hitchhike to their terminal destination
where they facilitate local neuronal translation.
Challenges in the Interpretation of ALS
Genetics
The number of sequenced ALS cases and controls has grown
exponentially over the last decade such that the number of
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reported ALS genes has been doubling every 4 years [15].
This pace coincides with equally rapid advances in molecular
therapies like viral gene delivery or gene-silencing and anti-
sense oligonucleotides (ASOs) for gene downregulation or
splicing modifications. ASOs targeting SOD1, C9orf72, and
FUS are already in clinical trials, and several pharmaceutical
or biotech companies are expected to launch trials of AAV
vectors targeting SOD1 in the next year. As companies delib-
erate on which genes to target next, it is essential that the
genetic and functional evidence for reported genes be contin-
uously re-evaluated.
It is worth explicitly stating that our certainty that a gene
strongly influences ALS is correlated with the route by which
the ALS association was made and the length of time since the
gene was first reported (Fig. 1). Those genes that were identi-
fied in large family linkage studies are clearly causative even
on the strength of a single reported mutation (e.g., SOD1,
C9orf72, VAPB, SETX). Other genes have been securely im-
plicated when smaller unrelated families show segregation of
the same mutation (TARDBP, FUS), when multiple different
mutations produce the same molecular defect (KIF5A, TBK1),
or when the mutations reported in smaller families cluster
regionally within protein domains (UBQLN2). With rare-
variant burden testing and GWA studies, the strong evidence
comes from the unbiased nature of the approach, the statistical
power of genome-wide association, and replication.
For many ALS genes reported from candidate gene se-
quencing efforts or found in small families, the evidence is
not as definitive. In many cases, the literature consists of var-
iants unique to ALS patients identified by sequencing many
simplex/sporadic patients. If variants have been found in fa-
milial cases, only rarely has DNA been available from other
individuals for segregation testing. Even when a second af-
fected individual is available for testing, it is typically a first-
degree relative who has a 50% chance of sharing any variant,
ALS-related or not. In the absence of clear-cut evidence from
the genetic data, neuropathological signatures can strengthen
the case for gene pathogenicity (e.g., aggregates of the
ANXA11 gene product exclusive to mutation carriers [53] or
the remarkable number of Lewy body–like inclusions found
in TIA1 carriers [54]). Unfortunately, the number of genes
where even a single mutation carrier has had neuropatholog-
ical assessment is small. Finally, experimental data from func-
tional studies or animal modeling can be useful in interpreting
the importance of these genes. In ALS, even for genes with
long-standing and incontrovertible evidence for monogenic
causation, recapitulating disease features in mice or finding
reproducible cellular phenotypes in patient-derived stem cell
models have been challenging. For many of the uncertain
ALS genes, there is some experimental data showing func-
tional effects of some ALS-associated mutations, sometimes
even in the robustly implicated pathways outlined earlier.
However, the specificity of the demonstrated defects is almost
never investigated for the gene variants that were also found in
controls. Thus, there is uncertainty on the status of data for
individual genes which is represented in Fig. 1 by color cod-
ing. These assignments are based on interpretation of the cur-
rent literature, but other experts may feel more or less confi-
dent in particular individual genes based on their own
weighting of the available evidence. The important point of
the color-coding is to emphasize that not every gene reported
to cause ALS and appearing on a timeline shares the same
level of certainty.
Recently Discovered ALS Genes
As many of the newly discovered genes account for smaller
proportions of the ALS population and have only recently
been discovered, most have yet to have their neuropathologi-
cal phenotypes studied or been studied in model systems.
Further studies are clearly warranted to fully understand the
functional consequences of these gene mutations.
TBK1: TBK1 (TANK-binding kinase 1) plays important
roles in autophagy and activation of innate immunity and is
a direct regulator of optineurin, another ALS-associated gene
[42, 55]. It was the first gene for ALS identified using rare
variant burden collapsing [56] in a predominantly sporadic
cohort and was subsequently validated by a similar approach
in familial ALS [57]. The strongest signal in both studies came
from loss of function mutations, several of which have shown
segregation in large families or been found in multiple studies.
Thus, loss-of-function mutations in TBK1 are a clearly
established cause of ALS. Several single amino acid deletions
have been reported and may be acting by reducing its phos-
phorylation [58]. Individual studies and meta-analysis [59]
have confirmed increased risk with missense variants but im-
plicating specific mutations has been challenging: only a sin-
gle missense mutation (p.Arg573Gly) has shown segregation
in familial disease (primary lateral sclerosis or FTD, [60]).
Therefore, at this time, the pathogenicity of specific missense
changes in TBK1 is impossible to ascertain in the absence of
segregation or clear functional data [61]. Indeed, some mis-
sense variants from ALS patients impair TBK1 signaling [57,
58]. Given the challenges of interpreting the pathogenicity of
missense changes, it is difficult to estimate how common
TBK1-induced ALS is. A German cohort reported around
1% of LOF mutations in FALS [62].
TBK1mutations carriers show typical ages at onset, sites at
onset, and rates of progression but appear to have higher rates
of cognitive involvement and frank FTD [10]. Mutation car-
riers with FTD alone have been reported [63]. In fact, TBK1
may be the second only to C9orf72 in frequency among pa-
tients with ALS and FTD [64]. Atypical phenotypes, includ-
ing primary lateral sclerosis [60], progressive supranuclear
palsy (PSP) [65], cerebellar ataxia [66], and corticobasal
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degeneration [67] have also been described. PSP and ataxia in
individuals carrying a single amino acid deletion also reported
in ALS-FTD and for which functional loss-of-function data
exists [58].
TUBA4A: TUBA4A is a major constituent protein of mi-
crotubules, essential for cytoskeletal integrity and axonal
transport. TUBA4A was first implicated in ALS by burden
testing methods in a large familial ALS cohort with confirma-
tion in a second cohort [52]. Unfortunately, all pedigrees with
potential mutations were too small or lacked DNA for defin-
itive segregation of any single mutation. Among the other
reported rare TUBA4A variants is p.A383T, found in both an
Italian FALS patient and a sporadic patient of Chinese ances-
try [67]. Other investigations in familial ALS or FTD have
found few or no additional TUBA4A mutations [68, 69], and
burden testing in large cohorts have not demonstrated an as-
sociation in sporadic patients (ALSdb and Project Mine). The
functional effects of only a few mutations in TUBA4A have
been examined in cell culture systems. Not surprisingly, some
variants demonstrate impaired microtubule network assembly
and r educ t i on s i n m i c r o t ubu l e s t a b i l i t y [ 52 ] .
Neuropathological analysis of mutation carriers has not been
reported, but tubulin A4A is not clearly mislocalized in spinal
cord from sporadic ALS patients [52]. To date, patients with
putative mutations in TUBA4A have shown spinal onset with
typical upper and lower motor neuron involvement and only a
small number have had cognitive impairment or FTD [52, 67,
68].
KIF5A: KIF5A is a kinesin, a microtubule-associated mo-
tor protein, responsible for organelle transport, including ly-
sosomes and mitochondria, and missense mutations in the N-
terminal motor domain of KIF5A have long been known to
cause spastic paraplegia type 10/CMT2 (SPG10/CMT2)
[70–73]. Recent evidence links loss-of-function mutations in
the C-terminal cargo binding domain to ALS. This evidence
came from both the largest GWAS in ALS to date and two
rare variant burden analyses in familial ALS cohorts [19••,
49]. ALS-associated mutations were found to cluster at the
3′ end of the gene where they disrupt splicing of exon 27
and disrupt the C-terminal cargo binding domain. Loss of
the cargo-binding domain or haploinsufficiency presumably
disrupts axonal transport in some fashion, though this has yet
to be demonstrated. The neuropathology of KIF5A loss-of-
function carriers has not been reported. ALS patients with
loss-of-functionmutations inKIF5A show a lower age at onset
(46 vs 65 years) and a remarkably long survival (10 vs.
3 years) [19••]. It should be noted that while the strongest
association is ALS with C-terminal loss-of-function mutations
and SPG10/CMT2 with N-terminal missense mutations, there
have been some individuals within SPG10/CMT2 families
presenting with ALS phenotypes, raising the possibility that
even missense KIF5A mutations in the N-terminal motor do-
main can present with ALS [74].
ANXA11: ANXA11 is involved in the calcium-dependent
formation of vesicles and potentially mRNA tethering for
transport along axons. Its association with ALS was discov-
ered when whole exome data from 50 family ALS cases were
overlapped for recurrently mutated genes or variants [53].
This analysis “rediscovered” p.M337V in TARDBP and also
revealed a second mutation—p.D40G in ANXA11. This mu-
tation was identified in additional patients with ALS and rep-
resents a shared European founder. Post-mortem analysis of a
single p.D40G mutation carrier showed large cytoplasmic in-
clusions of insoluble ANXA11 protein [53]. However, the
most definitively causative mutations do not seem to enhance
aggregation of ANXA11, but instead disrupt calcyclin bind-
ing. There is also evidence that some mutations impair the
ability of ANXA11 to tether RNA granules to actively
transported lysosomes [75]. ANXA11 mutations are rare in
ALS, the handful of reported patients showing typical ALS
features. Only a single individual has had clinically apparent
dementia [75].
TIA1: TIA1 is an RNA-binding protein like TARDBP and
FUS, with a key role in the formation of stress granules.
Mutations in TIA were already associated with a distal myop-
athy with vacuoles (just like other ALS genes VCP, MATR3,
HNRNPA2B1). Whole-exome sequencing in a small ALS-
FTD family identified a segregating TIA1 variant in the low-
complexity domain and subsequent analysis of this specific
region in cases and controls showed a statistical burden of rare
variants in ALS cases [43]. Targeted sequencing in several
Chinese ALS cohorts have identified other rare mutations in
this region of TIA1, but no segregating mutations have been
reported [76, 77]. Attempts to replicate this genetic association
within three larger cohorts have been unsuccessful [29••, 78,
79••], emphasizing that more investigation is needed.
However, there are strong indications from neuropathologic
evaluation that TIA1 mutations contribute to ALS pathogen-
esis. Nine individuals with seven different TIA1 mutations
(P362L; M334I; A381T; G355R; V294M; V360M; A381T)
in the TIA1 gene showed a remarkably consistent pathological
phenotype characterized by frequent round eosinophilic,
Lewy body–like inclusions [54] in addition to widespread
TDP-43 aggregation. In addition to this shared unique pathol-
ogy, almost all reported carriers have had clinical FTD in
addition to ALS.
CCNF: CCNF encodes cyclin F, a member of the FBOX
family of proteins and serves as the substrate-binding module
of the SKP1-CUL1-F-box protein (SCF) ubiquitin ligase com-
plex. In this role, it binds substrates and directs their
ubiquitylation for subsequent degradation by the ubiquitin
proteasomal pathway. CCNF was linked to ALS when
single-nucleotide polymorphism (SNP) and microsatellite
linkage analyses in a large Australian family pointed to
Chromosome 16p13.3 and whole-exome sequencing identi-
fied p.S621G in CCNF [80]. Other rare or even novel variants
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have been identified in other cohorts, but none of them have
been recurrent or shown to segregate with disease. Mutations
reported in ALS do not alter cyclin F stability or disrupt for-
mation of the SCF complex [47], but in vitro can increase the
ATPase activity of VCP (another ALS-causative gene) while
others impair ubiquitin-mediated proteasomal degradation
[47]. Either mechanism disrupts the normal processing of
TDP-43, leading to its abnormal cytoplasmic accumulation
[47, 81]. The strongest effect occurred with the clearly segre-
gating mutation (p.S621G), which also disrupts Lys48-
specific ubiquitylation and impairs autophagy [81]. When
expressed in zebrafish, this mutation also induced increased
spinal cord neuronal cell death, impaired motor axonal length,
and produced a motor deficit [82]. In sum, the functional anal-
ysis of cyclin F supports pathogenicity of the only segregating
mutation (p.S621G), with work yet to be done in clarifying
whether other identified mutations are causative. The entire
spectrum of ALS-FTD has been reported in individuals with
rare variants in CCNF with no standout features to date, and
neuropathological evaluation has yet to be reported [80].
DNAJC7: DNAJC7 encodes a heat-shock protein co-
chaperone known to regulate key protein-folding chaperones
Hsp70 and Hsp90 with roles in neuroprotect ion.
Understanding of DNAJC7’s role in protein folding and qual-
ity control has largely been in the context of steroid hormone
regulation, but there is emerging evidence that it may suppress
cellular responses to innate immunity [83]. Gene-based bur-
den methodologies demonstrated enrichment of premature
truncation variants in DNJAC7 [28]. The discovery of
DNAJC7 was enabled by the aggregation of three previous
ALS whole-exome datasets into a much larger collaborative
cohort with unprecedented power. This illustrates the impor-
tant fact that further gene discovery in ALS will require in-
creasing cooperation and harmonization across the many ge-
netic projects in the field and makes the case for open-access
models of data production and sharing. Premature truncating
muta t ions in DNAJC7 a re presumed to ac t v ia
haploinsufficiency, but functional investigations have not
been reported. Similarly, the neuropathological and clinical
phenotypes of mutation carriers are yet to be described.
NEK1:NEK1 (NIMA related kinase 1) is a serine/threonine
kinase involved in cell-cycle regulation, axonal development,
and implicated in axonal polarity and axon guidance as well as
DNA damage repair [84, 85]. Loss-of-function mutations
were first implicated in ALS by gene burden testing in a most-
ly sporadic cohort [56] but then validated in two independent
familial cohorts of European ancestry [84, 86] and in a
Chinese population [87]. The weight of evidence, as with
TBK1 and OPTN, favors loss-of-function mutations as causa-
tive, but rare missense variation also modestly increases risk
[86], especially the p.Arg261His variant [84, 88]. How loss of
NEK1 function or missense mutations lead to ALS is not yet
known, but may lead to the accumulation of DNA damage
that contributes directly to cell damage and cell death in neu-
rons that are already vulnerable due to widespread protein
misfolding, as demonstrated in cell culture [89]. It is also
possible that NEK1 mutations directly contribute to protein
misfolding. Indeed, insoluble SOD1 aggregates were recently
reported in an ALS case with a NEK1 R812X mutation at
post-mortem [90]. Detailed phenotypic information for either
loss-of-function or missense variant carriers has not been
published.
C21orf2: The biological role of C21orf2 (or CFAP410) is
poorly understood, but limited evidence suggests that it func-
tions in DNA damage control and repair similar to NEK1 and
plays a role in cilia formation [91]. Its drosophila homolog is
implicated in actin structure [92], with possible relevance to
ALS genes like TUBA4A, PFN1, KIF5A, and ANXA11.
C21orf2 was identified in a large genome-wide association
study of common variation [19••] with subsequent replication
in a large cohort study [12]. The same study also used gene
burden testing to demonstrate an excess of rare non-
synonymous C21orf2 variants in patients with ALS. To date,
segregating or recurrent mutations have not been reported,
making it difficult to interpret the pathogenicity of individual
mutations. Investigations into the functional implications of
ALS-associated variants have only recently begun, with struc-
tural modeling suggesting that a fraction of them are likely to
disrupt the protein structure [93]. The clinical and neuropath-
ological phenotypes of ALS patients carrying C21orf2 muta-
tions have not yet been reported.
LGALSL: LGALSL encodes a galectin-related protein
whose function is largely unknown. As with most of the
new genes highlighted in this review, LGALSL was identified
using gene burden methods on whole-exome sequencing.
Unlike other discoveries however, this study used burden test-
ing methods capable of implicating mutational hotspots or
domains rather than entire genes [29••]. As has been the case
for most other gene burden methods, loss-of-function muta-
tions were the strongest association with ALS. This very re-
cent report has not yet been replicated, and no mutations seg-
regating in familial ALS or ALS-FTD have yet been reported.
A subsequent paper demonstrated LGALSL variants in
0.382% of cases and 0.068% of controls, hence identifying
it as a non-significant candidate [56]. In the initial paper, car-
riers of LGALSL mutations had significantly early age at
symptom onset (13 years earlier than average for the cohort)
but were otherwise typical of ALS. Neuropathology of muta-
tion carriers has not been reported. If future studies confirm an
association between LGALSL and ALS, this gene could im-
plicate an entirely new biological pathway in ALS
pathogenesis.
GLT8D1: GLT8D1 is a ubiquitously expressed glycosyl-
transferase of unknown function implicated in ALS by family-
based whole-exome analysis and candidate gene sequencing
[94]. Study of a small ALS family identified a disease-
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associated haplotype containing rare missense mutations in
two genes, ARPP21 and GLT8D1 [94]. The same haplotype
was found in additional ALS patients, along with a much
smaller number of patients who carried one or the other mu-
tation, but not both. The identification of two ALS patients
with other rare variants in exon 4 of GLT8D1 made this gene
statistically more likely to be causative, but a role for ARPP21
has not been excluded. The authors hypothesized there could
be a synergistic effect between the two mutations.
Interestingly, a study in Chinese patients found a non-
significant enrichment of mutations in ARPP21 but not
GLT8D1 [95], making further study of these two genes essen-
tial for clarifying their role in ALS. ARPP21 is an RNA-
binding protein with known roles in neuronal dendrite elabo-
ration [96], while GLT8D1 is a ubiquitously expressed glyco-
syltransferase of unknown function. Missense variants dem-
onstrate a mild deficit in enzyme activity and, in an overex-
pression model, induce a mild increase in cytotoxicity in vitro
and impaired locomotion in zebrafish [95]. As with LGALSL,
conclusive implication of GLT8D1 would highlight a previ-
ously unexplored pathway in ALS pathogenesis. The small
number of cases reported thus far makes phenotypic patterns
tentative, but plausible as mutation carriers showed earlier
onset of disease and those carrying both mutations on the
haplotype (GLT8D1 and ARPP21) trended toward shorter
survival.
Conclusions and Future Directions
Recent advances in understanding the complex genetic archi-
tecture of ALS have been the direct consequence of global
collaborative approaches to gather large cohorts with harmo-
nized, well-curated clinical information from a large number
of sites. It is therefore crucial that this continues and that there
is a standardized approach to such collaborative efforts with
the adoption of comparable methodologies, open access to
data, and an emphasis on high-quality genetic and biological
validation. Even with these concerted efforts, the genes iden-
tified will be rare in the ALS population and the mutations
difficult to interpret on the bases of genetic data alone. This
argues that concerted efforts for neuropathological evaluation
and model systems to assess functional effects of mutations
will be increasingly important in the interpretation of ALS
genetic variants.
This review highlights the importance of ongoing aggrega-
tion of datasets through data sharing and collaboration at the
very inception of large-scale genomic investigation to im-
prove ascertainment of structural variants, somatic variation,
copy number variation, and novel repeats contributing to dis-
ease. Future studies exploring these large datasets, including
the potential application of artificial intelligence, will need to
focus on the development of capabilities to interpret non-
coding variation with robust and reproducible effect sizes.
Also, the collection of longitudinal data may facilitate the
identification of key associations with disease progression
and other phenotypic traits, which would generate promising
targets for molecularly directed personalized therapies.
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